We are live on ! Find out more
Opus Point Partners Management

Opus Point Partners Management Portfolio holdings

AUM $55.3M Turnover 18.46%
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
-11.1%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$55.3M
AUM Growth
-$12.2M
Cap. Flow
-$3.77M
Cap. Flow %
-6.81%
Top 10 Hldgs %
62.56%
Holding
65
New
2
Increased
18
Reduced
1
Closed
10
Avg Time Held Equity + Options
2.1 years
Top 10 Avg Time Held Equity + Options
0.8 years
Top 20 Avg Time Held Equity + Options
1.3 years
Avg Time Held Equity only
2.1 years
Top 10 Avg Time Held Equity only
0.9 years
Top 20 Avg Time Held Equity only
1.5 years

Sector Composition

Rank Sector Weight
1 Healthcare 56.66%
2 Miscellaneous 43.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
EXEL icon
51
Exelixis
EXEL
$16.9B
$232K 0.42%
13,132
+1,692
+15% +$34.2K
2018 Q2
5 quarters
ALKS icon
52
Alkermes
ALKS
$7.87B
$227K 0.41%
+11,632
New +$253K
2019 Q3
0 quarters
RARE icon
53
Ultragenyx Pharmaceutical
RARE
$1.79B
$217K 0.39%
5,064
– –
2016 Q1
14 quarters
KYNB icon
54
Kyntra Bio
KYNB
$7.49M
$212K 0.38%
230
+35
+18% +$38.4K
2017 Q4
7 quarters
SCTL
55
DELISTED
Societal CDMO
SCTL
$126K 0.23%
12,659
– –
2016 Q4
11 quarters
AGIO icon
56
Agios Pharmaceuticals
AGIO
$1.76B
– –
-4,806
Closed -$240K –
ANAB icon
57
AnaptysBio
ANAB
$1.39B
– –
-6,116
Closed -$345K –
BLUE icon
58
DELISTED
bluebird bio
BLUE
– –
-451
Closed -$743K –
FOLD icon
59
DELISTED
Amicus Therapeutics
FOLD
– –
-36,731
Closed -$458K –
INSM icon
60
Insmed
INSM
$26.5B
– –
-26,936
Closed -$690K –
MDGL icon
61
Madrigal Pharmaceuticals
MDGL
$9.42B
– –
-3,570
Closed -$374K –
PCRX icon
62
Pacira BioSciences
PCRX
– –
-11,250
Closed -$489K –
SRPT icon
63
Sarepta Therapeutics
SRPT
$1.58B
– –
-5,353
Closed -$813K –
VKTX icon
64
Viking Therapeutics
VKTX
$3.4B
– –
-48,485
Closed -$402K –
IMMU
65
DELISTED
Immunomedics
IMMU
– –
-62,575
Closed -$868K –

Similar funds

Opus Point Partners Management's Q3 2019 Portfolio in Review

As of Q3 2019, Opus Point Partners Management held 65 positions worth $55.3M, down 18% from $67.6M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Opus Point Partners Management withdrew a net $3.77M in Q3 2019, closing 10 positions and reducing 1 holding. Its most notable exit was Immunomedics, an estimated $868K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 59% a quarter earlier, followed by Miscellaneous.

Against the trend, Opus Point Partners Management opened a new position in United Therapeutics worth $279K.

  • Opus Point Partners Management's largest Q3 2019 buy was United Therapeutics: 3,498 shares worth $279K.
  • Opus Point Partners Management added most to Fortress Biotech in Q3 2019, an estimated $595K increase.
  • Opus Point Partners Management's biggest Q3 2019 reduction was Intercept Pharmaceuticals, cutting an estimated $131K.
  • Opus Point Partners Management fully exited Immunomedics in Q3 2019, selling an estimated $868K.
  • Opus Point Partners Management's ten largest holdings make up 63% of its $55.3M portfolio in Q3 2019.
  • Opus Point Partners Management opened 2 new positions and closed 10 in Q3 2019.
  • Opus Point Partners Management's portfolio value fell 18% quarter-over-quarter to $55.3M.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.